Member Info for SamJSung

My reading of the latest Annual Report : We can expect an announcement sooner rather than later regarding The Medication Adherence Division.. I suspect it will be sold and this should make the remaining two divisions even more attractive to a Predator .. With 2 experienced Finance in the guise of CEO and CFO and substantial options just waiting to be triggered by any any successful takeover... I do believe that QP will soon be in play... This is all conjecture, but the CEO is doing his job by focusing on both profitability and Growth... who knows, but when the sale of the Medication division is completed .. there should be a substantial reduction in remaining group debt and funds available to grow further the core assets of the company.

I suspect that weak holders are selling on the lack of news... But and a big but as Cadburyhill highlights and the Annual report states.. For LOXL2 We are very pleased with the progress that has been made in this programme; this is an exciting area scientifically.We are encouraged by the significant level of interest in this programme from potential licensees, who will be following the Phase I trial developments closely.. We are particularly interested in using inhaled IFN-beta in COPD. the underlying biology in COPD, the high clinical need, and new diagnostic technology presents us with an attractive opportunity to explore the drug’s full potential. H2 2017 could prove very interesting and possibly rewarding for remaining shareholders who continue to keep the faith.

Spot on Robins.... but his Options can also be realised if the Company is taken over... hopefully at a Substantial Premium.... either way it in both his interests and the Board's interest to ensure substantially improved shareholder value sooner rather than later...

For those that kept the faith.... A pretty good day for QP's share price... Whist there is a lot of ground to recover,...the potential for further substantial positive movements in the share price should not be underestimated...Once the company has reduced to its two most profitable Pillars..QP could possibly obtain Growth Stock status, A return to dividend payments and become a very attractive takeover candidate.. All to play for here !

From AISHAH on the ADVFN bulletin Board 14.19 today... A great article ! htTp://www.fool.co.uk/investing/2017/05/03/this-emerging-growth-business-looks-too-cheap/

These could include Redundancy Costs, Termination of Employment contracts, Legal costs,... There has been substantial changes in the composition of the QP Board (replacing CEO, FD, Chairman, Non Exec Director etc) and the legal payments due to such individuals when they resign ( 12 months pay ?) There was also a not insubstantial payment to the recruitment Agency for the new CFO.

Very Large share trades continue to go through the market.. No RNS's yet as to who sold and importantly who is the buyer / buyers of these large blocks.

Once the company has been streamlined down to 2 core pillars.... with all loss making units divested or sold.. I would suspect that the Company would be very attractive to a larger player / predator... Once The transformation of the company is complete which should be completed by 18/19.. the take our price as a guess should be north of £1 per share... This would reward the major institutions for their risk capital (approx 300% return) .. and the Senior management team for their achievement via their not inconsiderable option plans...

My suspicion is the Slater has closed his position completely in QP shares...Lets see who the buyer is.. this should be interesting to discover.

I expect the sell off / divestment of QP's Medication Adherence Division very soon.. Chris Rigg states We are well-placed to deliver future growth by focusing on our core Niche and Specials businesses."

I was expecting a lot worse.... Ian Johnson, Non-executive Chairman of Quantum, said: "This year's results draw a line under the past performance of the Group. They mark the transition to a more focused and simplified business led by a new Board, and demonstrate real progress in executing our strategy. The Board is confident in the future prospects of the Group and we look forward to reporting on further strategic progress as we move forward."... Nicely put !

Apologies Robins.. have just seen the RNS regarding Slater's reduced holding.. you are correct... very strange that a sale of 1000000 shares were sold today.. .. 2 late trades of of 250000 and a 150000 appear as buys (well to me at least at 43.79p and 43p..... well we know who sold... importantly who bought? Where are the rset of Slaters sale .. with the Market Makers ? or with another major holder?

Robins ... Your observation is not quite correct... AIM companies only need to update their major shareholder register twice a year.. and this is one of those updates... We do NOT know when the Major shareholding changes took place... sometime between between Jan and End of March 2017...Not Yesterday... For example.. Slater reduced his holding by 805,501.. from 3.60% to 3.13% NOT 2.49% L&G increased their holding by 727000 shares Aviva reduced by 50000 Cavendish increased their holding by 173860 The total % held by Major shareholders in Jan 2017 was 67.22% and at the end of March 2017 was 67.26 a slight increase..

There is obviously demand for the shares.. I would be interested to know who is the seller of the large buys we see going through the market... We might even be reaching the point where any overhang of shares is now minimal and large purchases are going to move the share price strongly forward...The new Board of Directors will ensure that the year end balance sheet has every possible right off known to man... Allowing the new management team to start with a near clean bill of health for year 17/18... The trading update for the current period should (I expect) to be conservatively positive... possibly even understating the progress made allowing a positive announcement for half year 17/18 results,, The Major shareholder register when updated should tell a very interesting story... who has increased, who has (if anybody) reduced... It would not surprise me to see a potential stalker in the wings... QP operates in a very desirable set of Niche Markets... and this should / would be attractive to a larger player.. The Omens appear to looking far brighter than for some time..Wednesday should be very interesting

Putting the current issues regarding the results of the Astra P11 Clinical trial to one side..the following from the SNG latest Presentation (March 2017) is very interesting...and subject to successful completion of Toxicology testing .. Phase I clinical trials scheduled to start in H2 2017.. Whilst again no Guarantee's of success here can be taken it is worth looking at the potential .. and it is significant of revenue that could be earned by SNG's involvement ... The slide below gives details of deals around Fibrosis struck with Pharma Majors. They are very significant in monetary terms... It is worth I believe remaining on the bus to see the outcome of SNG Fibrosis journey.. For those wanting to see the full presentation.. http://www.synairgen.com/media/1346/introduction-to-synairgen-march-2017v2.pdf Develop an anti-fibrotic LOXL2 inhibitor for Idiopathic Pulmonary Fibrosis (IPF) • High LOXL2 is associated with more rapid disease progression • Recent deal in Fibrosis include: o Discovery stage  Boehringer Ingelheim 2016 collaboration with Inventiva to develop targets for IPF. Deal value up to €170m plus tiered royalties o Phase I  Gilead buys Nimbus Therapeutics in 2016 for Liver fibrosis programme $0.4bn up front and up to $0.8bn future payments o Phase II  Allergan buys Tobira Therapeutics in 2016 for Liver fibrosis programme $0.6bn up front and up to $1.1bn future payments  Bristol-Myers Squibb enters an agreement in 2015 providing exclusive rights to acquire Promedior Inc for up to $1.25bn o Post approval  Roche acquired Intermune in 2014 for $8bn, main programme was pirfenidone for IPF, and other anti-fibrosis programmes

A disappointing outcome from Astra's P2 trial... and hence the fall in SNG's share price... Whilst SNG want to examine in detail the data collected at Phase 2... Next steps for Interferon may be many months down line... Whilst one should not allocate blame to any one individual.. I feel that Richard Marsden's SNG's CEO's time is now up... SNG need a CEO who can create manage and develop multiple partnerships with a variety of UK / International Pharma Groups... He has not leveraged the assets and IP of SNG to the full..e.g SNG's BioBank Technology Platform,This Platform I believe might be worth substantially more than the current Market Cap to the right Pharma who is also interested in Asthma related compounds... Likewise the ground work relating to Interferon and its current data both in house and when available from Astra could form the basis of a joint / replacement compound with a large Pharma .. LOXL2 is a potential money spinner.. if the lead into Phase 1 trials prove successful. With Neil Woodford a major stakeholder it should not be too difficult to introduce SNG to potential partners both UK and Global.. Richard Marsden has tried and failed and a new more dynamic and innovative CEO is required who can both make it happen .. and see the possibilities that SNG can offer to the wider Pharma Industry...Shareholders with vision that can see the possibilities should (if possible) stay the course.. and wait for good fortune to smile on shareholders.

Robins... We have to remember that Next week will detail the Final Results for Full Year 17.. which finished end of Jan 2017..Half year results for 2018 are not due until Oct 2017 when we will also receive a trading update...The Post Year end update in the Annual report should tell us all / most of the things that concern us both...With the majority if not all the bad news already out... Initial results of the new strategy together with key product / service updates and progress on the( global) Company's partnership (s) programme will make very interesting reading... It would not surprise me if the major shareholders are not also considering a merger / takeover strategy for QP to obtain the maximum return for their shareholding allowing them to move onto their next target...

Robins, don't look back look forward... Scaife and the ex CFO paid for their poor performance with their jobs and the substantial reduced value of their shareholdings / options. The interesting question to ask is 'What residual value (if any) does Nupharm offer to QP shareholders, be it leases, land value, tax losses etc?The benefits of NuPharm closure should be a more focused group, improved profitability and a group more attractive to either a merger partner or a takeover... The results in May will be very interesting.

Robins - Agree with your summary, another positive might be an update on progress with Licensing Agreement for MED2002 as a Special Product from Futura Medical plc... this agreement allows Futura's novel treatment for erectile dysfunction, will soon be available as an unlicensed medicine .. This should be a real money spinner .. It might even open up the thought of Futura and QP merging to become a unique business entity

Rylidan.... Agree with you.. The movement of the QP Offer Price since the begining of April17 has been minimal..it remains betwen 40 - 42p.. There does appear to be an appetite to hoover up all sells coming on the market.. but by whom and why.? The Major share register of QP has not been updated since end of Jan 2017, so we do not have sight of which major shareholder is selling down or adding to their holding.. Apparently AIM shares only need to update their Major shareholder register no more than twice a year..Possibly to stop any false markets being created or wild variations in share price resulting..The 3rd May should prove very informative on many levels.. I am very interested in how Biodose is or not progressing...and the critical need for QP to have a portfolio of partners both national and global to promote its portfolio... Its sales strategy should be Selling With Partners , Selling through Partners and Selling directly where possible.. Multiple channels to market.. If the current Management team cannot achieve this.. other organisations will be waiting in the wings to deliver premium results at the expense of current shareholders... We will see !!!